Drug Approval for Painful Heart Condition Expands to Kids

(MedPage Today) -- The FDA expanded its approval of mavacamten (Camzyos) to include children with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten thus becomes the first cardiac myosin inhibitor indicated for pediatric patients...